Navigation Links
Medicago succesfully expresses VLP antigen for A H1N1 strain
Date:5/12/2009

QUEBEC CITY, May 12 /PRNewswire-FirstCall/ - Medicago Inc. (TSX-V: MDG), a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has successfully expressed a new VLP antigen ("H1 VLP") from the influenza A (H1N1) strain that caused the recent Influenza outbreak in North America and other countries. The antigen was expressed within 14 days of receiving the DNA sequence with the Company's VLP vaccine technology and Proficia(TM) manufacturing technology.

Initial results show that the new H1 VLP is comparable to other VLPs recently expressed by Medicago such as the New Caledonia strain (H1N1) and Brisbane strain (H1N1). The primary goal of this initiative was to confirm, in a real case-scenario, Medicago's initial development timelines. Medicago requires the genetic sequence of the virus, limiting delays that may happen with traditional systems. The H1 VLP will be purified in preparation for an immunogenicity study in mice. The Company expects results from this study in June, with the goal of confirming the immunogenic potential of this H1 VLP.

"We are thrilled with these initial results. They demonstrate that we can rapidly express an antigen from a new influenza strain without modifying our current technology and could potentially be a first responder solution in the face of a pandemic," said Louis-Philippe Vezina, Chief Scientific Officer of Medicago. "Our ultimate goal is to provide a rapid approach to vaccine production allowing for immediate access to the antigens of emerging influenza strains. Current influenza vaccine manufacturing technologies can take up to six months to produce a vaccine for a new strain. With our proprietary technology we believe we can potentially cut development time up to five months."

About Medicago

Medicago is committed to provide highly effective and affordable vaccines based on proprietary Virus-Like Particle (VLP) and manufacturing technologies. Medicago is developing VLP vaccines to protect against H5N1 pandemic influenza, using a transient expression system which produces recombinant vaccine antigens in non-transgenic plants. This technology has potential to offer advantages of speed and cost over competitive technologies. It could deliver a vaccine for testing in about a month after the identification and reception of genetic sequences from a pandemic strain. This production time frame has the potential to allow vaccination of the population before the first wave of a pandemic strikes and to supply large volumes of vaccine antigens to the world market. Additional information about Medicago is available at www.medicago.com.

Forward Looking Statements

This press release contains forward-looking statements which reflect Medicago's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. Medicago disclaims any obligation to update these forward-looking statements.

    Neither TSX Venture Exchange nor its Regulation Services Provider (as
    that term is defined in the policies of the TSX Venture Exchange) accepts
    responsibility for the adequacy or accuracy of this release


'/>"/>
SOURCE Medicago Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Medicago initiates work on Swine Flu strain
2. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
3. U.S. Government Accepts $192 Million of sanofi pasteur H5N1 Bulk Vaccine Antigen for Pandemic Stockpile
4. Antigen Discovery Inc. Awarded a SBIR Phase II Grant to Commercialize Novel Antigens for Serodiagnostic Products and Vaccine Development
5. PharmAthene Response to DHHS Request for Proposals for Recombinant Protective Antigen Anthrax Vaccine Deemed Technically Acceptable and Within Competitive Range for Procurement Consideration
6. Pepscan Achieves a Breakthrough With CLIPS Immunogen Technology: Synthetic Peptide Antigen is Able to Induce Fully Functional Antibodies Against a Formerly Intractable GPCR Target CXCR7
7. Scientists develop strategy to rapidly describe outbreak strains with next-generation DNA sequencing
8. Stretching silicon: A new method to measure how strain affects semiconductors
9. NIST stress tests probe nanoscale strains in materials
10. Seasonal Influenza Activity Increasing Across Europe - H3N2 Dominant Strain
11. NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... August 18, 2017 , ... OAI, ... Semiconductor, MEMS, and Microfluidics Industries, announces the new Model 800E front and backside, ... in automated production mask aligners. OAI has already received and installed several ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... the Fluidnatek® Electrospinning and Electrospraying line of nanofiber ... from table-top equipment for the lab to fully automated pilot plants and ...
(Date:8/16/2017)... , ... August 16, 2017 , ... ... U.S. Food and Drug Administration (FDA) inspection at our Dilworth, MN site. The ... was issued. This inspection was conducted as part of a routine Bioresearch Monitoring ...
(Date:8/15/2017)... ... , ... Kapstone Medical is proud to announce that it has ... and inventors develop and safeguard their latest innovations. The company has grown from ... of clients in the United States and around the world. , Company Founder ...
Breaking Biology Technology:
(Date:3/29/2017)...  higi, the health IT company that operates the ... , today announced a Series B investment from ... The new investment and acquisition accelerates higi,s strategy to ... population health activities through the collection and workflow integration ... collects and secures data today on behalf of over ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access ... 15.1% over the next decade to reach approximately $1,580 million by ... and forecasts for all the given segments on global as well ...
(Date:3/22/2017)... 21, 2017 Optimove , provider ... retailers such as 1-800-Flowers and AdoreMe, today announced ... and Replenishment. Using Optimove,s machine learning algorithms, these ... and replenishment recommendations to their customers based not ... of customer intent drawn from a complex web ...
Breaking Biology News(10 mins):